Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany.
Division of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University Hospital Würzburg, Röntgenring 11, Würzburg, 97070, Germany.
Oncogene. 2018 Jul;37(30):4122-4136. doi: 10.1038/s41388-018-0265-5. Epub 2018 Apr 30.
Attempts to exploit the cytotoxic activity of death receptors (DR) for treating cancer have thus far been disappointing. DR activation in most malignant cells fails to trigger cell death and may even promote tumor growth by activating cell death-independent DR-associated signaling pathways. Overcoming apoptosis resistance is consequently a prerequisite for successful clinical exploitation of DR stimulation. Here we show that hyperosmotic stress in the tumor microenvironment unleashes the deadly potential of DRs by enforcing BCL-2 addiction of cancer cells. Hypertonicity robustly enhanced cytotoxicity of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and other DR ligands in various cancer entities. Initial events in TRAIL DR signaling remained unaffected, but hypertonic conditions unlocked activation of the mitochondrial death pathway and thus amplified the apoptotic signal. Mechanistically, we demonstrate that hyperosmotic stress imposed a BCL-2-addiction on cancer cells to safeguard the integrity of the outer mitochondrial membrane (OMM), essentially exhausting the protective capacity of BCL-2-like pro-survival proteins. Deprivation of these mitochondrial safeguards licensed DR-generated truncated BH3-interacting domain death agonist (tBID) to activate BCL-2-associated X protein (BAX) and initiated mitochondrial outer membrane permeabilization (MOMP). Our work highlights that hyperosmotic stress in the tumor environment primes mitochondria for death and lowers the threshold for DR-induced apoptosis. Beyond TRAIL-based therapies, our findings could help to strengthen the efficacy of other apoptosis-inducing cancer treatment regimens.
目前,试图利用死亡受体 (DR) 的细胞毒性活性来治疗癌症的尝试令人失望。在大多数恶性细胞中,DR 的激活未能引发细胞死亡,甚至可能通过激活与细胞死亡无关的 DR 相关信号通路促进肿瘤生长。因此,克服细胞凋亡抵抗是成功临床利用 DR 刺激的前提条件。在这里,我们表明肿瘤微环境中的高渗应激通过迫使癌细胞对 BCL-2 产生依赖性来释放 DR 的致命潜力。高渗条件强烈增强了肿瘤坏死因子 (TNF) 相关凋亡诱导配体 (TRAIL) 和其他 DR 配体在各种癌症实体中的细胞毒性。TRAIL DR 信号转导的初始事件不受影响,但高渗条件下激活了线粒体死亡途径,从而放大了凋亡信号。从机制上讲,我们证明高渗应激使癌细胞对 BCL-2 产生依赖性,以保护外线粒体膜 (OMM) 的完整性,实质上耗尽了 BCL-2 样的促生存蛋白的保护能力。剥夺这些线粒体保护物允许 DR 产生的截断 BH3 相互作用结构域死亡激动剂 (tBID) 激活 BCL-2 相关 X 蛋白 (BAX),并启动线粒体外膜通透性 (MOMP)。我们的工作强调了肿瘤环境中的高渗应激使线粒体为死亡做好准备,并降低了 DR 诱导的细胞凋亡的阈值。除了基于 TRAIL 的治疗方法外,我们的发现还有助于增强其他诱导细胞凋亡的癌症治疗方案的疗效。